PMC9082737_01
Longitudinal imaging of case 1. (a) Longitudinal CT images. CT scan before transdermal scopolamine patches 1st use: 3.8 cm pleural effusion. CT scan 1 months after 1st use: 1.9 cm pleural effusion. CT scan before 2nd use 2.0 cm pleural effusion. CT scan 1 months after 2nd use: 0.9 cm pleural effusion. (b) Neck CT images before and after tracheoesophageal diversion for the prevention of aspiration. (c) Representative image after tracheoesophageal diversion.. CT: computed tomography; TDS: transdermal scopolamine.
10.1177_2050313X221096227-fig1.jpg
PMC9082737_01_10.1177_2050313X221096227-fig1.jpg
fig1-2050313X221096227
Furthermore, right pulmonary consolidation decreased, and bilateral dorsal ground-glass opacities and atelectasis improved (Figure 1(a) and Table 1).   Transdermal scopolamine was discontinued after 1 month of continuous use. Ultimately, in February 2020, the man's family chose tracheoesophageal diversion after consulting with an otolaryngologist for the prevention of aspiration at home after discharge because the use of transdermal scopolamine was off-label (Figure 1(b)).
PMC9082737_02
Longitudinal CT examinations of (a) case 2 (CT scan pre scopolamine patches: 2.0 cm pleural effusion. CT scan 7 months after: 0.7 cm pleural effusion) (b) case 3 (CT scan pre scopolamine patches: 3.0 cm pleural effusion. CT scan 2 months after: 0.7 cm pleural effusion), and (c) case 4 (CT scan pre scopolamine patches: 3.4 cm pleural effusion. CT scan 7 months after: 1.8 cm pleural effusion).. CT: computed tomography; TDS: transdermal scopolamine.
10.1177_2050313X221096227-fig2.jpg
PMC9082737_04_10.1177_2050313X221096227-fig2.jpg
fig2-2050313X221096227
CT, the right pleural effusion decreased, and bilateral dorsal pulmonary ground-glass opacities improved after transdermal scopolamine use (Figure 2(c) and Table 1). Continuous oxygen use was not required after transdermal scopolamine, and pneumonia did not recur until 17 months later with continuous use of scopolamine.
PMC9082737_03
Longitudinal CT examinations of (a) case 2 (CT scan pre scopolamine patches: 2.0 cm pleural effusion. CT scan 7 months after: 0.7 cm pleural effusion) (b) case 3 (CT scan pre scopolamine patches: 3.0 cm pleural effusion. CT scan 2 months after: 0.7 cm pleural effusion), and (c) case 4 (CT scan pre scopolamine patches: 3.4 cm pleural effusion. CT scan 7 months after: 1.8 cm pleural effusion).. CT: computed tomography; TDS: transdermal scopolamine.
10.1177_2050313X221096227-fig2.jpg
PMC9082737_04_10.1177_2050313X221096227-fig2.jpg
fig2-2050313X221096227
CT, the right pleural effusion decreased, and bilateral dorsal pulmonary ground-glass opacities improved after transdermal scopolamine use (Figure 2(c) and Table 1). Continuous oxygen use was not required after transdermal scopolamine, and pneumonia did not recur until 17 months later with continuous use of scopolamine.
PMC9082737_04
Longitudinal CT examinations of (a) case 2 (CT scan pre scopolamine patches: 2.0 cm pleural effusion. CT scan 7 months after: 0.7 cm pleural effusion) (b) case 3 (CT scan pre scopolamine patches: 3.0 cm pleural effusion. CT scan 2 months after: 0.7 cm pleural effusion), and (c) case 4 (CT scan pre scopolamine patches: 3.4 cm pleural effusion. CT scan 7 months after: 1.8 cm pleural effusion).. CT: computed tomography; TDS: transdermal scopolamine.
10.1177_2050313X221096227-fig2.jpg
PMC9082737_04_10.1177_2050313X221096227-fig2.jpg
fig2-2050313X221096227
CT, the right pleural effusion decreased, and bilateral dorsal pulmonary ground-glass opacities improved after transdermal scopolamine use (Figure 2(c) and Table 1). Continuous oxygen use was not required after transdermal scopolamine, and pneumonia did not recur until 17 months later with continuous use of scopolamine.